Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 25, 2022 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

Apr 21, 2022 9:05am EDT

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

Apr 19, 2022 9:05am EDT

Lexaria Commences Multi-Week Human Clinical Hypertension Study

Apr 14, 2022 8:45am EDT

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

Apr 12, 2022 9:10am EDT

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

Apr 11, 2022 9:00am EDT

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

Mar 15, 2022 2:05pm EDT

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

Mar 08, 2022 9:15am EST

Lexaria Granted Important New Oral Nicotine Patent

Feb 02, 2022 9:25am EST

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

Jan 27, 2022 9:35am EST

Lexaria Provides Annual Letter From the CEO

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 20
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top